ZENLABS.BO · BSE
Zenlabs Ethica Limited
₹28.45
-3.59% (-₹1.06)
Prev. close
₹29.51
Volume
323
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Zenlabs Ethica Limited
Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, Singapore, Brunei, Timor-Leste, Bangladesh, and internationally. The company was formerly known as Neelkanth Technologies Limited and changed its name to Zenlabs Ethica Limited in January 2016. Zenlabs Ethica Limited was incorporated in 1993 and is based in Chandigarh, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Sanjeev Kumar Singal
Headquarters
Chandigarh
Employees
66
Website
zenlabsethica.comExchange
View on BSE ↗Key stats
Market cap
₹18.47 Cr
EPS (TTM)
₹-3.90
Beta (1Y · daily vs NIFTY 50)
1.08
Beta (5Y · monthly vs NIFTY 50)
0.33
Shares float
21.10 L
EPS · quarter ended Jun 2026
₹-0.88
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹56.64 Cr | ₹69.09 Cr | ₹66.89 Cr | ₹58.56 Cr | ₹51.42 Cr | ₹46.92 Cr | |
| EBITDA | ₹1.24 Cr | ₹2.52 Cr | ₹2.46 Cr | ₹2.68 Cr | ₹2.60 Cr | ₹-12.53 L |
| ₹83.20 L | ₹82.30 L | ₹48.93 L | ₹42.12 L | ₹26.92 L | ₹-1.94 Cr | |
| Diluted EPS | — | — | ₹0.75 | ₹0.65 | ₹0.41 | ₹-2.97 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹43.49 Cr | ₹40.26 Cr | ₹40.62 Cr | ₹37.21 Cr | |
| — | — | ₹5.84 Cr | ₹14.86 Cr | ₹12.70 Cr | ₹10.98 Cr | |
| Stockholders' equity | — | — | ₹9.70 Cr | ₹10.12 Cr | ₹10.43 Cr | ₹8.51 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1.52 Cr | ₹-9.06 Cr | ₹3.83 Cr | ₹4.06 Cr | |
| Investing cash flow | — | — | ₹-1.47 Cr | ₹10.90 L | ₹13.50 L | ₹12,000 |
| — | — | ₹6.03 L | ₹8.24 Cr | ₹-3.08 Cr | ₹-2.95 Cr | |
| Capital expenditure | — | — | ₹-1.55 Cr | ₹-2.21 L | ₹-1.76 L | ₹-39,000 |
| End cash position | — | — | ₹1.62 Cr | ₹90.50 L | ₹1.79 Cr | ₹2.90 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Zenlabs Ethica Limited | ₹19.21 Cr | ₹29.51 | — | 2.26 | -22.7% | 1.29 | -8.8% | -5.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 19
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Zenlabs Ethica Q1 Results FY27: Net Loss Rs 0.57 Cr, Revenue Rs 14 Crore
Univest · 1 month ago